

AMENDMENT

In the Specification:

Please amend the paragraph appearing at page 1, lines 6-13 as follows:

Relation back and Priority Information

This is a continuation of U.S. Ser. No. 08/466,163, filed on June 6, 1995, now allowed U.S.P. 6,329,509 B1, which is a division of U.S. Ser. No. 08/405,617, filed on March 15, 1995, which is a continuation of U.S. Ser. No. 08/185,899, filed on January 26, 1994, now abandoned, which is a 35 U.S.C. § 371 of PCT/US92/06860, filed on August 14, 1992, which is a continuation-in-part of both U.S. Ser. No. 07/879,495, filed on May 7, 1992, now abandoned and U.S. Ser. No. 07/744,768, filed on August 14, 1991, now abandoned; all of which are incorporated by reference and to which application priority is claimed under 35 U.S.C. § 120.

Please amend the paragraphs appearing at page 6, lines 7-13 as follows:

Brief Description of the Figure

FIG. 1 depicts the sequence of human IgE Fc ϵ 2 and Fc ϵ 3 (~~SEQ-ID~~ SEQ ID NO: 1). This particular sequence is from Padlan *et al.*, Molec. Immun., 23:1063-1075 (1986). Residues are numbered according to Kabat (*supra*). "X" residues are included to align the Padlan IgE sequence with the Kabat numbering scheme. Sequences which were altered in preparing various IgE mutants are underlined; bold numbers below the lines denote the mutant number. β -strand residues are overlined; loop residues are defined by all residues intervening between two β -strands.

Fig. 2 depicts light and heavy chain sequences for MAE11 (~~SEQ-ID~~ SEQ ID NOS: 2 and 3), MAE13 (~~SEQ-ID~~ SEQ ID NOS: 4 and 5) and MAE15 (~~SEQ-ID~~ SEQ ID NOS: 6 and 7).

Fig. 3 depicts heavy and light chain sequences for HuMae11V1 (~~SEQ-ID~~ SEQ ID NOS: 8 and 9).

Please amend the paragraph appearing at page 25, lines 4-6 as follows:

Exemplary IgE variants are set forth in Table 5. It will be understood that this table may contain variants that bind to both receptors, differentially to one or the other, or to neither receptor.

Please amend the paragraph appearing at page 37, lines 29-32 as follows:

Each of the IgE specific antibodies was further tested in cell-based and plate assays to select for antibodies which bound to IgE in such a way as to inhibit IgE binding to FCEH and which are not capable of binding to FCEH-bound IgE. The results of these assays are set forth in Table 5~~6~~ and Table 5a~~6a~~ below.

IN eDAN
SPEC
12/22/2003
DO NOT
ENTER DB